Previous 10 | Next 10 |
Phase III clinical trial of [ 18 F]flurpiridaz PET diagnostic radiopharmaceutical meets co-primary endpoints for detecting Coronary Artery Disease (CAD) Trial also met its first key secondary endpoint, demonstrating higher diagnostic efficacy for [ 18 F]flurpiridaz PET compare...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips For those investors interested in small-cap stocks to buy, you might steer clear of tech names. At least, that’s according to the analysts at Jefferies . Jefferies analyst Steven DeSanctis recently dis...
NORTH BILLERICA, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc . (“the Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative diagnostics, targeted therapeutics and artificial intelligence solutions that...
B Riley has resumed coverage of Lantheus Holdings ( NASDAQ: LNTH ) with a buy citing the company's growth trajectory due to the the launch of Pylarify, a prostate-specific membrane antigen (PSMA) targeting positron emission tomography ( PET ) imaging agent. The firm ha...
Earnings season winds down after producing the best S&P performance since 2009. The recently passed tax and spend green energy bill does not contain a scintilla of "growth". That means any recovery remains rocky at best. China's zero COVID policy continues to take its toll on ...
Stock market expectations have shifted to a relatively more benign Federal Reserve rate outlook, thus driving a sharp rally. The market is approaching a key technical level. Healthcare has relatively outperformed the market and has been consolidating. Biotechs found a bottom a...
As the market begins to show signs of recovery in the second half of 2022, there are 3 growth stocks that are offering investors a chance to realize capital appreciation. AerSale is about to commercialize its AerAware heads-up aircraft cockpit display technology and has realized a 72%...
Lantheus Holdings, Inc. (LNTH) Q2 2022 Earnings Conference Call Aug 4, 2022 8:08 AM Company Participants Mark Kinarney - Senior Director, Investor Relations Mary Heino - President and Chief Executive Officer Robert Marshall - Chief Financial Officer and Treasurer...
The following slide deck was published by Lantheus Holdings, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Lantheus Holdings, Inc. 2022 Q2 - Results - Earnings Call Presentation
The biotech industry for the first half of the year had seen better six-month periods in the past, but the situation appears to have changed beginning in July. From Jan. 1 to June 20, 2022, the SPDR S&P Biotech ETF ( XBI ) and iShares Nasdaq Biotechnology ETF ( IBB ) had...
News, Short Squeeze, Breakout and More Instantly...
Lantheus Holdings Inc. Company Name:
LNTH Stock Symbol:
NASDAQ Market:
Lantheus Holdings Inc. Website:
2024-08-01 08:00:12 ET David Turkaly from JMP Securities issued a price target of $125.00 for LNTH on 2024-08-01 07:13:00. The adjusted price target was set to $125.00. At the time of the announcement, LNTH was trading at $104.83. The overall price target consensus is at...
Second Quarter 2024 Worldwide revenue of $394.1 million, an increase of 22.5% from second quarter 2023 Completed three strategic transactions to expand innovative pipeline GAAP fully diluted earnings per share of $0.88, compared to $1.33 in second quarter 2023. Adjusted fully ...
BEDFORD, Mass., July 17, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, July 31, 2024, to discuss its financial and operating results for the second...